<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03085966</url>
  </required_header>
  <id_info>
    <org_study_id>MNWK2016-08-04</org_study_id>
    <nct_id>NCT03085966</nct_id>
  </id_info>
  <brief_title>Autologous Immune Cell Therapy in Combination With LHRH-a in Patients With mCRPC</brief_title>
  <official_title>Study of Autologous Immune Cell Therapy in Combination With the Luteinizing Hormone Releasing Hormone Agonists (LHRH-a) in Patients With Metastatic Castration-resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cellular Biomedicine Group Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cellular Biomedicine Group Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study of autologous immune cell therapy in combination with the luteinizing hormone releasing&#xD;
      hormone agonists (LHRH-a) in patients with metastatic castration-resistant prostate cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Autologous dendritic cells (DC) are known to activate other immune cells, such as central&#xD;
      memory T cells (Tcm cells), that are able to mount an attack against cancer cells. The&#xD;
      purpose of this study is to evaluate the feasibility, safety and efficacy of patients' own&#xD;
      immune cells combined with the luteinizing hormone releasing hormone agonists (LHRH-a) for&#xD;
      treatment of metastatic castration-resistant prostate cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">February 27, 2017</start_date>
  <completion_date type="Anticipated">December 27, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 27, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AE and SAE</measure>
    <time_frame>24 months</time_frame>
    <description>Incidences of adverse events or serious adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>24 months</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>24 months</time_frame>
    <description>Progression-Free Survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Metastatic Castration-resistant Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>autologous immune cell therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Luteinizing Hormone Releasing Hormone Agonists (LHRH-a) and Autologous dendritic cells (DC) and central memory T cells (Tcm cells)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous immune cell therapy</intervention_name>
    <description>Luteinizing Hormone Releasing Hormone Agonists (LHRH-a) and Autologous dendritic cells (DC) and central memory T cells (Tcm cells)</description>
    <arm_group_label>autologous immune cell therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males age ≥ 18 years；&#xD;
&#xD;
          -  Subjects who understand and sign the consent form for this study；&#xD;
&#xD;
          -  Metastatic， castrate resistant, histologically confirmed prostate cancer；&#xD;
&#xD;
          -  PSA&gt; 5ng / ml；&#xD;
&#xD;
          -  Serum testosterone ≤ 17nmol / L (50ng / dl)；&#xD;
&#xD;
          -  Expected survival time of at least 24 months；&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1；&#xD;
&#xD;
          -  Subjects did not receive chemotherapy, radiation therapy, surgery and other treatment&#xD;
             within 4 weeks；&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject has an allergic history of medicine or food；&#xD;
&#xD;
          -  The patient with more serious heart disease, including but not limited to myocardial&#xD;
             infarction, cardiomyopathy, valvular disease, malignant arrhythmia；&#xD;
&#xD;
          -  Hb &lt;9.0 g / 100ml, WBC &lt;3 ×10^9/ L, LY &lt;1.0 x10^9/ L, platelet &lt;100,000 / mm3；&#xD;
&#xD;
          -  Patients with immune disease or auto-immune disease (such as Multiple sclerosis,&#xD;
             systemic lupus erythematosus，rheumatoid arthritis and inflammatory bowel disease,&#xD;
             vitiligo )；&#xD;
&#xD;
          -  The subject has uncontrolled or hard-to-control diseases of liver, or kidney system；&#xD;
&#xD;
          -  Patient with visceral metastases, pathological fractures, spinal cord compression&#xD;
             symptoms；&#xD;
&#xD;
          -  Severe pain associated with bone metastases (VAS score ≧ 4 points)；&#xD;
&#xD;
          -  Patient has received immunotherapy (including but not limited to PD-1 / PDL-1, etc.)；&#xD;
&#xD;
          -  patient with irregular hemorrhagic disease；&#xD;
&#xD;
          -  Subject is HIV, hepatitis B virus, hepatitis C virus, Treponema pallidum infection；&#xD;
&#xD;
          -  Subject has uncontrollable seizures, or because of mental loss of self-knowledge and&#xD;
             so on；&#xD;
&#xD;
          -  The subject has an history of other malignant tumor；&#xD;
&#xD;
          -  The patient had drug abuse, drug abuse, and long history of alcoholism in the 12 years&#xD;
             prior to this trial；&#xD;
&#xD;
          -  The subject has participated in any other clinical trial in the 3 months prior to this&#xD;
             trial；&#xD;
&#xD;
          -  The subject has any other unsuitable or adverse condition to be determined by the&#xD;
             investigator.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dingwei Ye</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dingwei Ye</last_name>
    <email>dwyeli@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai Shi</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dingwei Ye</last_name>
      <email>dwyeli@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>March 9, 2017</study_first_submitted>
  <study_first_submitted_qc>March 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2017</study_first_posted>
  <last_update_submitted>March 15, 2017</last_update_submitted>
  <last_update_submitted_qc>March 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>central memory T cell</keyword>
  <keyword>metastatic castration-resistant prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

